ArticleCancer communications (London, England)2023

Low level of ARID1A contributes to adaptive immune resistance and sensitizes triple-negative breast cancer to immune checkpoint inhibitors.

Xin-Yu Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.